ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Letter to the Editor
Acute uric acid nephropathy during DA-EPOCH-R therapy in primary mediastinal large B-Cell lymphoma
Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive lymphoma subtype that predominantly affects young adults and is commonly treated with dose-adjusted EPOCH-R (DA-EPOCH-R), which provides high response and cure rates. Despite its efficacy, intensive chemotherapy regimens may lead to rare but clinically significant metabolic and renal complications. Here, we report a case of acute kidney injury (AKI) developing during DA-EPOCH-R therapy, most consistent with isolated acute uric acid nephropathy in the absence of classical tumor lysis syndrome (TLS).

Keywords : Primary mediastinal large B-cell lymphoma, acute kidney injury, uric acid nephropathy, tumor lysis syndrome, DA-EPOCH-R, acyclovir nephrotoxicity

Download Article
Informed Consent

Written informed consent was obtained from the patient for the publication of this correspondence and any related clinical details.

Author Contributions

Concept: MBÖ, MKY; Design: SÇ, MKY; Control: MKY; Data Collection and/or Processing: MBÖ, SÇ, UÇ; Analysis and/or Interpretation: UÇ, AG, SÇ; Literature Review: MBÖ; Article Writing: MBÖ, SÇ; Critical Review: MBÖ, MKY, SÇ, UÇ, AG.

Conflict of Interest

The authors declare no conflicts of interest.

Financial Disclosure

No financial support was received for the preparation or publication of this letter.

Editor Note

Serhat Çelik is a member of the Editorial Board of this journal. He was not involved in the editor assignment, reviewer selection, peer review process, or editorial decision for this manuscript. The peer review process was managed independently by another editor.


1. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416. doi:10.1056/NEJMoa1214561
2. Camus V, Rossi C, Sesques P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma. Blood Adv. 2021;5(19):3862-3872. doi:10.1182/bloodadvances.2021004778
3. Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of patients with PMBCL treated with DA-EPOCH-R. Br J Haematol. 2017;179(5):739-747. doi:10.1111/bjh.14951
4. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11. doi:10.1111/j.1365-2141.2004.05094.x
5. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999; 106(4):459-465. doi:10.1016/s0002-9343(99)00041-8
6. Kwong YD, Hsu RK. Antivirals in herpes zoster and AKI: old foes, new insights. Clin J Am Soc Nephrol. 2024;19(6):685-687. doi:10.2215/CJN.0000000000000480
7. Boosman RJ, Bosman RJ, van der Voort PHJ, Franssen EJF. Evaluation of aciclovir-induced nephrotoxicity in critically ill patients: a propensity-matched cohort study. J Clin Med. 2025;14(5):1409. doi:10.3390/jcm14051409
Article available in :
Volume 4, Issue 4, 2026
Page : 96-97
https://doi.org/10.51271/ICJIM-0085
Article Information
Received : 15 May 2026
Accepted : 23 Eki 2026
Published : 28 Eki 2026
Corresponding Author :

Murat Bekir Özyurt: Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye

[email protected]
Citation : Özyurt MB, Çalış U, Çelik S, Güneş A, Kurt Yüksel M. Acute uric acid nephropathy during DA-EPOCH-R therapy in primary mediastinal large B-cell lymphoma. Intercont J Int Med. 2026;4(4):96-97. doi:10.51271/ICJIM-0085

Read: 7
Download : 5
Cited: 0
_Footer